Target intelligence / Profile preview

Hepatitis B virus large surface protein (pre-S2 domain) (null)

Target
null
Molecular classification
Viral envelope protein domain, Surface antigen domain, Other (not a receptor, enzyme, nor transcription factor per se)
01

Overview

The *pre-S2 domain* is a 55-amino acid region found within the middle (MHBs) and large (LHBs) envelope proteins of hepatitis B virus. HBsAg proteins are essential for virus particle assembly, morphogenesis, and infectivity. The pre-S2 domain acts mainly as a structural spacer, supporting proper folding and capsid binding during viral envelope formation[3][5]. Mutations in the pre-S2 region can facilitate immune escape and affect serological detection[5]. The surface antigen proteins, containing pre-S2, are key diagnostic biomarkers and targets for both vaccination and therapeutic intervention. Drug interactions occur primarily through neutralizing antibody recognition or, in the case of entry inhibitors, through the NTCP receptor rather than direct pre-S2 targeting. Pre-S2 mutants have been associated with adverse liver disease outcomes and may complicate therapy or disease monitoring[1][5][7].

Other names
HBV pre-S2 domainpre-S2 region of hepatitis B surface antigenHBV surface protein middle domain
02

Mechanism of action

Inhibition of viral entry by blocking envelope protein-receptor interaction (e.g., NTCP) Neutralization of virus via antibody binding to HBsAg containing pre-S2 domains

03

Biological functions

Viral morphogenesisVirus assembly (functions as a spacer in envelope protein conformational changes)Capsid binding during virion envelopmentAntigenicity
04

Disease associations

Infection (HBV infection)Immune escape (contains mutations relevant for vaccine escape)Other (involvement in liver pathology, e.g., hepatitis, hepatocellular carcinoma by cytopathic or immune mechanisms)
05

Safety considerations

Mutant pre-S2 forms associated with increased risk of liver disease and vaccine escapeImmune tolerance, leading to occult infection or failure of immune clearance
06

Interacting drugs

Nucleotide/nucleoside analogs (target HBV replication, not directly pre-S2, but interfere with envelope protein function)

2 more in the full profile.

07

Biomarkers

HBsAg serology (pre-S2 is part of HBsAg used as a diagnostic/prognostic marker)Pre-S2 mutant detection in serum (linked to disease progression and immune escape)

Beyond the preview

Go deeper on Hepatitis B virus large surface protein (pre-S2 domain) (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatitis B virus large surface protein (pre-S2 domain) (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call